Alterity Therapeutics Ltd
PRNAF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001131343
In the last 90 days, Alterity Therapeutics Ltd insiders filed 1 open-market purchase and 0 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Other share classesATHE
Key figures
- Insider buysLast 90 days, $23.8K in total
- 1
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026
- 0
- 13F valueReported value at the end of Q2 2026
- $0
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding PRNAF, Q2 2026
No superinvestor reported holding PRNAF at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Alterity Therapeutics Ltd insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 (view filing)7:01 PM ET | Aug 31 | 8 daysLate | Marks Peter AshleyDirector | PPurchase | +47.6K | $0.50 | +$23.8K | +33.1%191.3K after | |
| Sep 8, 2026 (view filing)7:01 PM ET | Aug 31 | 8 daysLate | Marks Peter AshleyDirector | PPurchase | −47.6K | $0.50 | −$23.8K | –0 after | DerivativeDuplicate filing |
| Sep 8, 2026 (view filing)6:52 PM ET | Aug 31 | 8 daysLate | Stamler David AllenChief Executive Officer | PPurchase | −47.6K | $0.50 | −$23.8K | –0 after | Derivative |
Top 10 13F holders, Q2 2026
The largest institutional positions in Alterity Therapeutics Ltd at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding PRNAF in 13F filings for Q2 2026.